Christopher Barker
As seen in:
Color Research & Application,
Nature,
Wiley Online Library,
Taylor & Francis Online,
JAMA (The Journal of the American Medical Association),
JAMA Network,
Diabetes Magazine,
HMP Global Learning Network,
Journal of The American Academy of Dermatology (JAAD),
International Journal of Radiation Oncology*Biology*Physics
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Christopher
Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Unconventional skyrmions in synthetic antiferromagnets
Abstract Magnetic skyrmions are topologically protected spin textures that can act as reconfigurable nanoscale information carriers. In synthetic antiferromagnets, interlayer exchange coupling provides a control parameter beyond the interfacial Dzyaloshinskii–Moriya interaction and magnetic anisotropy. Here we engineer a synthetic antiferromagnet of two chemically distinct ferromagnets, CoB and CoFeB, in which the external field and interlayer exchange act asymmetrically on the sublattices.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
|
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma Abstract Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice.
By Bina Kassamali, Jonathan D Schoenfeld, Rosh K. Sethi, Richard Bakst, Christopher Barker, Alok Bhatt, Carol R. Bradford, Paul Bunch, David Carr, John Carucci Verified, Sunandana Chandra, Michelle Chen Verified, Karen Connolly, Addison M. Demer, Bently P. Doonan, Kevin S. Emerick, Ben Friedman, Thomas J. Galloway, Jessica Geiger, Jeffrey P. Guenette, Hillary Kelly, Nikhil I. Khushalani, Laurie L. Kohen, Shlomo Koyfman, Kim O Learned, Justin J. Leitenberger, Elizabeth J. Lilley, John Lukens, Theresa Medina, Devarati Mitra, David M. Ozog, Itai Pashtan, Nancy Pham, Divya Srivastava, Paul L. Swiecicki, Charlotte Taylor, Matthew E. Witek, Ashley Wysong, David Zander, Ann W. Silk, Anokhi Jambusaria-Pahlajani, Emily Ruiz, Linna L. Gali, Shweta Sharat Kumar
|
JAMA Network
Verified
Integrating Adjuvant Therapy in High-Risk CSCC
Dr Wong: I think it's particularly important to have that recognition of who falls into the very highest risk category, especially since now we can do something about it, right? Now that we have the data indicating that the addition of cemiplimab after definitive local treatment can be helpful in decreasing further recurrences, then it's really important for us to try to be as precise as possible to ensure that we're capturing all the patients who could benefit from this.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Christopher
Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack